Home | About PM | Editorial board | Search | Ahead of print | Current Issue | Archives | Instructions | Subscribe | Advertise | Contact us |  Login 
Pharmacognosy Magazine
Search Article 
  
Advanced search 
 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 14  |  Issue : 56  |  Page : 351-358

Efficacy of Momordica charantia L. on blood glucose, blood lipid, and body weight: A meta-analysis of randomized controlled trials


1 Social Pharmacy Research Unit, Faculty of Pharmacy, Mahasarakham University, Kantharawichai, Maha Sarakham, Thailand
2 Pharmaceutical Chemistry and Natural Products Research Unit, Faculty of Pharmacy, Mahasarakham University, Kantharawichai, Maha Sarakham, Thailand

Correspondence Address:
Wiraphol Phimarn
Social Pharmacy Research Unit, Faculty of Pharmacy, Mahasarakham University, Kantharawichai, Maha Sarakham 44150
Thailand
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/pm.pm_215_17

Rights and Permissions

Background: Previous studies reported that Momordica charantia (MC) improves several metabolic parameters, yet outcomes from numerous trials are contradictory. Objectives: This study aimed to assess MC efficacy for improving glycemic status, lipid profile, and body weight. Materials and Methods: The databases included PubMed, Cochrane Register of Controlled Trials, Scopus, CINALH, AMED, ThaiLIS, and Thai Medical Index, from inception to June 2016. References from retrieved articles were also evaluated. For this analysis, we selected randomized placebo versus controlled intervention trials conducted in humans dosed with various forms of MC, excluding studies where patients coadministered other medications. We performed a quality assessment of the retrieved studies using Jadad's scoring and Cochrane's risk of bias assessment. Results: Eight studies (507 participants) met inclusion criteria, which included six randomized controlled trials (RCTs). Meta-analysis revealed a reduction in fasting blood sugar (FBS) (weight mean difference [WMD] −25.03 mg/dL; 95% confidence interval [CI] −41.17,-8.89) and hemoglobin A1C (HbA1C), favoring MC (WMD −0.20%; 95% CI −0.36, −0.04). Similar results were observed for LDL-C (WMD −5.86 mg/dL; 95% CI: −10.83, −0.89), total cholesterol (WMD −6.29 mg/dL; 95% CI: −10.64, −1.93), and triglyceride (WMD −16.22 mg/dL; 95% CI: −26.40, −6.04). Moreover, patients administering MC experienced a significant reduction in body weight (WMD v3.45 kg; 95% CI −6.73, −0.16). Conclusions: MC may improve fasting blood glucose levels, lipid profile, or body weight. A large, well-designed RCT and head-to-head comparison using a standardized preparation of MC will provide definitive data on specific participants. Abbreviations used: ACROBAT: A Cochrane risk of bias assessment tool, WMD: Weight mean difference, CI: Confidence interval, SDs: Standard deviations, FBS: Fasting blood sugar, OGTT: Oral glucose tolerance test level; HDL: High-density lipoprotein, TC: Total cholesterol, TG: Triglyceride, BMI: Body mass index.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed3864    
    Printed52    
    Emailed0    
    PDF Downloaded237    
    Comments [Add]    

Recommend this journal